KOLESIE win this on the veto alone. The narrative around GenOne's five-game win streak is driving recreational money onto them, but look at who they beat: HEROIC Academy, ASTRAL, Leo, megoshort, EAC. KOLESIE's recent schedule includes SINNERS, TDK and FOKUS. The competition quality gap in that recent form is real.

The map pool argument is the core thesis. KOLESIE sit at 77% on Nuke across 13 maps. That is a genuine first-pick weapon. GenOne have played zero Mirage maps, which cripples their veto flexibility in a Bo3. They cannot comfortably counter-pick or force neutral ground, so the series structure tilts toward KOLESIE's preferred terrain. GenOne's Nuke win rate drops to 52% across 25 maps, and their Ancient comes in at just 38%. KOLESIE go 53% on Ancient and have the Nuke to fall back on. The maps GenOne would actually want to play here simply are not available to them.

The H2H is 2-1 KOLESIE. The price on KOLESIE reflects a market split between two books that have taken completely opposite views on the favorite, landing on a mechanical coin-flip that ignores the structural advantages sitting plainly in the map data. We are on KOLESIE.